In the case of KRAS, there is now clear evidence that alterations in allele frequencies or gene dosage at oncogene loci can have a dramatic impact upon tumorigenesis and tumor-associated phenotypes across tumor types (5, 6, 10). The gene discussed is KRAS; the disease is neoplasm.